Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PRLD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $258.63M
- EPS (TTM)
- -$0.59
- Dividend yield
- None
- 52-week range
- 1.30 – 6.83
- Day range
- 3.17 – 3.30
- Volume / Avg
- 299.25K / 432.74K
- Beta
- —
- Shares outstanding
- 65.34M
52-week range
PRLD stock today
On Nov 20, PRLD ended the session at $3.23, shedding $0.025 (0.77%), versus the S&P 500's 3.70% decline. At this level, PRLD sits in the middle of its 52-week range of $1.30 to $6.83: 52.7% below the high, set on Aug 24, 2026 and 149.4% above the low. PRLD is up 11.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 93.4%.
Prelude Therapeutics has posted a net loss over the last twelve months (EPS of -$0.59), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Prelude Therapeutics
Company profilePrelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Krishna Vaddi D.V.M., Ph.D.
- Headquarters
- Wilmington, DE
- Employees
- 79
- IPO year
- 2020
- Website
- preludetx.com
Financial highlights
Full financialsIn fiscal 2025, Prelude Therapeutics generated $12.1 million in revenue, up 73.4% from fiscal 2024. Prelude Therapeutics reported a net loss of $99.5 million, compared with a loss of $127.2 million a year earlier. Operating margin was -861.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $12.14M | $7.00M | — | — | — |
| Growth | +73.43% | — | — | — | — |
| Net income | $-99.50M | $-127.17M | $-121.83M | $-115.44M | $-111.69M |
| EPS (diluted) | $-1.29 | $-1.68 | $-2.02 | $-2.44 | $-2.43 |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$8.80+172.45%
- Strong buy 2
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.12 vs $-0.14
- Surprise
- +14.29%
PRLD news
All PRLD news- Prelude Therapeutics Incorporated Reports Third Quarter 2026 Financial ResultsNasdaq
- Prelude Q3 Loss Narrows On Lower R&D Costs; Breast Cancer Data Due In H2 2027NasdaqPRLD, MKC.V
- Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire
- Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?NasdaqTHC, PRLD, IMMX, KRSA
- Prelude Therapeutics to Participate in the Chardan Healthcare ConferenceGlobeNewswire
- Prelude Therapeutics, Lilly Partner To Evaluate PRT13722 In Breast Cancer TrialNasdaqLLY, PRLD
- Prelude, Lilly Partner On Breast Cancer Combination Trial; Stock UpNasdaqLLY, PRLD
- Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast CancerGlobeNewswire
Prelude Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EBSEmergent BioSolutions Inc. | 5.05 | -1.94% | $259.65M | vs PRLD |
| ALTAltimmune Inc. | 1.33 | -5.67% | $258.80M | vs PRLD |
| VCREVicore Pharma Holding AB ADR | 9.41 | -5.09% | $264.89M | vs PRLD |
| GALTGalectin Therapeutics Inc. | 2.69 | -4.27% | $271.35M | vs PRLD |
| QTTBQ32 Bio Inc. | 8.34 | -1.65% | $249.57M | vs PRLD |
| TTRXTurn Therapeutics Inc. | 8.10 | -6.31% | $247.49M | vs PRLD |
| LFCRLifecore Biomedical Inc. | 6.39 | +0.31% | $242.22M | vs PRLD |
| RLMDRelmada Therapeutics Inc. | 2.62 | -15.76% | $279.54M | vs PRLD |
Indexes, lists and sector
Prelude Therapeutics stock FAQ
What is Prelude Therapeutics's stock price today?
PRLD last traded at $3.23 as of Nov 20, 4:00 PM EST, down 0.77% on the day. Prices are delayed at least 15 minutes.
Who is Prelude Therapeutics's CEO?
Dr. Krishna Vaddi D.V.M., Ph.D. is the chief executive officer of Prelude Therapeutics Incorporated, which has about 79 employees.
What is the PRLD 52-week high?
The 52-week high for PRLD is $6.83 and the 52-week low is $1.30. The stock is currently 52.7% below its high.